Orexo AB
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Orexo AB sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Orexo AB: 4 sponsored US clinical trials, none currently recruiting.
Orexo AB sponsors 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 3 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opiate Dependence, with 1 trials.
Upper-quartile sponsor footprint
Orexo AB sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
4 total, page 1 of 1
OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder
NCT04948307
Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults
NCT01908842
Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence
NCT01903005
Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence
NCT01848054
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 2 |
| Phase 4 | 1 |
Therapeutic Areas
How the Orexo AB archive is shaped
4 indexed studies, none listed as recruiting (0% open); 4 completed (100%).
Phase mix: 3 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Opiate Dependence (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Orexo AB: archived-pipeline peers nationwide
Peers matched on 4 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Orexo AB sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 archived trials
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Orexo AB page
4 registered trials is a research-attention snapshot, not an endorsement of Orexo AB or any single study.
- None of Orexo AB's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Opiate Dependence is the condition Orexo AB studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opiate Dependence trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Orexo AB pipeline card: 4 registered trials from official public datasets.Report a data error.